{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001738","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2021-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.190977+00:00","generated_at":"2026-06-29T04:44:18.624202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q2 revenue $4.9M (+81% YoY); net loss $(13.5)M; raises ~$120M in July IPO","bullets":["Revenue $4.9M (+81% YoY); sold 25 LDDs and 1,825 LALs during Q2.","Net loss $(13.5)M ($(3.28)/share basic); adjusted net loss $(13.3)M ($(3.24)/share).","Gross loss $(0.8)M due to $1.7M inventory reserve for updated LAL with ActivShield.","Completed IPO in July 2021 raising ~$120M net proceeds; cash & equivalents $61.7M at June 30.","FDA approval and launch of LAL with ActivShield technology; new VP of U.S. Sales appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001738","json":"https://secwatch.observer/filing/0000950170-21-001738.json","markdown":"https://secwatch.observer/filing/0000950170-21-001738.md","text":"https://secwatch.observer/filing/0000950170-21-001738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017021001738/0000950170-21-001738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017021001738/rxst-20210909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:44:18.624202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}